Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

Similar articles for PubMed (Select 17002659)

1.

Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates.

Kempton CL, Soucie JM, Abshire TC.

J Thromb Haemost. 2006 Dec;4(12):2576-81. Epub 2006 Sep 26. Erratum in: J Thromb Haemost. 2007 Mar;5(3):657.

PMID:
17002659
2.

Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.

Mancuso ME, Mannucci PM, Rocino A, Garagiola I, Tagliaferri A, Santagostino E.

J Thromb Haemost. 2012 May;10(5):781-90. doi: 10.1111/j.1538-7836.2012.04691.x.

PMID:
22452823
3.

Epidemiology of inhibitors and current treatment strategies.

Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T; GTH PUP Study Group.

Haematologica. 2003 Jun;88(6):EREP04. Review.

PMID:
12826530
4.

A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group.

Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, Smit C, Strengers PF, Briët E.

Blood. 1993 Apr 15;81(8):2180-6.

5.

An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.

Shirahata A, Fukutake K, Higasa S, Mimaya J, Oka T, Shima M, Takamatsu J, Taki M, Taneichi M, Yoshioka A; STUDY GROUP ON FACTORS INVOLVED IN FORMATION OF INHIBITORS TO FACTOR VIII AND IX PREPARATIONS.

Haemophilia. 2011 Sep;17(5):771-6. doi: 10.1111/j.1365-2516.2011.02599.x. Epub 2011 Jun 20.

PMID:
21682824
6.

Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.

Strauss T, Lubetsky A, Ravid B, Bashari D, Luboshitz J, Lalezari S, Misgav M, Martinowitz U, Kenet G.

Haemophilia. 2011 Jul;17(4):625-9. doi: 10.1111/j.1365-2516.2010.02464.x. Epub 2011 Feb 7.

PMID:
21299743
7.

An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A.

Delumeau JC, Ikegawa C, Yokoyama C, Haupt V.

Thromb Haemost. 2008 Jul;100(1):32-7. doi: 10.1160/TH07-12-0724.

PMID:
18612535
8.

A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.

Rubinger M, Lillicrap D, Rivard GE, Teitel J, Carcao M, Hensman C, Walker I; Association of Hemophilia Clinic Directors of Canada.

Haemophilia. 2008 Mar;14(2):281-6. doi: 10.1111/j.1365-2516.2007.01634.x. Epub 2008 Jan 8.

PMID:
18194308
9.

Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.

Ettingshausen CE, Kreuz W.

Haemophilia. 2006 Dec;12 Suppl 6:102-6. Review.

PMID:
17123402
10.

Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.

de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D.

Thromb Haemost. 1994 May;71(5):544-7.

PMID:
8091377
11.

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

Sharathkumar A, Lillicrap D, Blanchette VS, Kern M, Leggo J, Stain AM, Brooker L, Carcao MD.

J Thromb Haemost. 2003 Jun;1(6):1228-36. Review.

PMID:
12871324
12.

Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.

Mauser-Bunschoten EP, Posthouwer D, Fischer K, van den Berg HM.

Haemophilia. 2007 Nov;13(6):697-700. Epub 2007 Sep 18.

PMID:
17877729
13.

Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.

Gouw SC, van den Berg HM, le Cessie S, van der Bom JG.

J Thromb Haemost. 2007 Jul;5(7):1383-90. Epub 2007 Apr 20.

PMID:
17456190
14.

Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).

Bacon CL, Singleton E, Brady B, White B, Nolan B, Gilmore RM, Ryan C, Keohane C, Jenkins PV, O'Donnell JS.

Haemophilia. 2011 May;17(3):407-11. doi: 10.1111/j.1365-2516.2010.02430.x. Epub 2011 Mar 8.

PMID:
21382134
15.

The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.

Auerswald G, Spranger T, Brackmann HH.

Haematologica. 2003 Jun;88(6):EREP05. Review.

PMID:
12826531
17.

Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.

Mauser-Bunschoten EP, van der Bom JG, Bongers M, Twijnstra M, Roosendaal G, Fischer K, van den Berg HM.

Haemophilia. 2001 Jul;7(4):364-8.

PMID:
11442640
18.

Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data.

Yoshioka A, Fukutake K, Takamatsu J, Shirahata A; Kogenate Post-Marketing Surveillance Study Group.

Int J Hematol. 2006 Aug;84(2):158-65.

PMID:
16926139
19.
20.

Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.

Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM; Emoclot15 Study Members.

Haemophilia. 2006 Mar;12(2):128-32.

PMID:
16476086
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk